Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) announced on Thursday that a combination regimen containing its antitumor agent, Imfinzi, was successful in a late-stage trial for a subset of patients with hepatocellular carcinoma, the most common type of liver cancer.
The EMERALD-3 Phase 3 trial
